- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07369089
Skierowane leczenie lekoopornej OUD z wykorzystaniem ketaminy wspomagającej ukierunkowaną na uważność terapię wzmacniania zdrowienia
KETAMORE: UKIERUNKOWANIE NA OUD OPORNE NA LECZENIE Z WSPOMAGANIEM KETAMINĄ W KIERUNKU ZWIĘKSZENIA EFEKTÓW ORIENTOWANEJ NA UWAŻNOŚĆ REGENERACJI
The goal of this clinical trial is to examine the usefulness of Mindfulness-Oriented Recovery Enhancement combined with Ketamine-Assisted Psychotherapy (KetaMORE) for individuals with opioid use disorder who are receiving medication treatment. The main question it aims to answer is whether individuals with opioid use disorder who receive Mindfulness-Oriented Recovery Enhancement in combination with Ketamine-Assisted Psychotherapy will demonstrate greater reductions in opioid use and craving than individuals who receive Ketamine-Assisted Psychotherapy with a non-mindfulness support group.
Participants will be randomly assigned to receive either Mindfulness-Oriented Recovery Enhancement combined with Ketamine-Assisted Psychotherapy or Ketamine-Assisted Psychotherapy combined with a support group control condition. Researchers will compare these groups on days of opioid use, time to first opioid use lapse, craving, and mood, assessed using ecological momentary assessments and standardized measures collected during treatment and follow-up.
Przegląd badań
Status
Warunki
Szczegółowy opis
This study is a Phase II, two-arm, parallel randomized controlled trial designed to evaluate the efficacy of Mindfulness-Oriented Recovery Enhancement combined with Ketamine-Assisted Psychotherapy (KetaMORE) compared to Ketamine-Assisted Psychotherapy paired with a support group control condition for individuals with opioid use disorder receiving medications for opioid use disorder (MOUD), including buprenorphine.
Participants will be randomized in a 1:1 ratio to one of two conditions: (1) Ketamine-Assisted Psychotherapy combined with Mindfulness-Oriented Recovery Enhancement, or (2) Ketamine-Assisted Psychotherapy combined with a support group providing nonspecific therapeutic support without mindfulness training. Both groups will receive identical ketamine dosing and psychotherapy components; the conditions will differ only in the adjunctive behavioral intervention.
Mindfulness-Oriented Recovery Enhancement is a manualized, evidence-based intervention integrating mindfulness training, cognitive reappraisal, and savoring techniques to reduce craving, negative affect, and maladaptive reward processing associated with substance use. The support group control condition is designed to match therapist contact and group support while excluding mindfulness-based content.
Participants will complete assessments at baseline, during treatment, post-treatment, and follow-up. Primary outcomes will include number of days of opioid use and time to first opioid use lapse. Secondary outcomes will include opioid craving and mood symptoms. Ecological momentary assessments will be used to capture daily fluctuations in substance use, craving, and affect throughout the study period.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Hannah Pfeffer, LMSW
- Numer telefonu: 619-500-4668
- E-mail: hapfeffer@health.ucsd.edu
Kopia zapasowa kontaktu do badania
- Nazwa: Kelly Hendrickson, MS
- E-mail: kehendrickson@health.ucsd.edu
Lokalizacje studiów
-
-
California
-
La Jolla, California, Stany Zjednoczone, 92093
- Rekrutacyjny
- University of California, San Diego
-
Kontakt:
- Hannah Pfeffer, LMSW
- Numer telefonu: 619-500-4668
- E-mail: hapfeffer@health.ucsd.edu
-
Główny śledczy:
- Eric Garland, PhD
-
Kontakt:
- Kelly Hendrickson, MS
- E-mail: kehendrickson@health.ucsd.edu
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84112
- Rekrutacyjny
- University Of Utah
-
Kontakt:
- Hannah Pfeffer, LMSW
- Numer telefonu: 619-500-4668
- E-mail: hapfeffer@health.ucsd.edu
-
Główny śledczy:
- Benjamin Lewis, PhD
-
Kontakt:
- Gina Gregovitch
- E-mail: Gina.Gregovich@hsc.utah.edu
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- English-speaking .
- DSM-5 criteria for Opioid Use Disorder (OUD).
- Documented evidence (by urine toxicology) of current illicit drug use (upon screening) or by self-report on the Addiction Severity Index (ASI).
- Men/Women >/= 18
- Current prescription of a buprenorphine-containing product.
- Have a support person that would be able to escort the subject home on the evening of the ketamine dosing session. The use of ride services will not be permitted (e.g., Uber, Lift, taxi, etc.).
- Agreement to adhere to Lifestyle Considerations
Exclusion Criteria:
-
1. A primary DSM-5 Axis I diagnosis of schizophrenia, schizoaffective disorder, dissociative identity disorder, or bipolar I/II disorder as determined by psychiatric evaluation.
2. Has baseline hypertension (≥160 SBP or ≥100 DBP), after repeated measurements. Note: Participants with hypertension that has been controlled by medication down to <160 Systolic blood pressure (SBP) and <100 diastolic blood pressure (DBP) will be allowed participate.
3. Has baseline abnormal resting heart rate (>100 or <60). 4. History of cardiovascular disease, including but not limited to clinically significant coronary artery disease, cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction, angina pectoris, coronary artery bypass graft or artificial heart valve, stroke, transient ischemic attack, or any clinically significant arrhythmia.
5. Has QTcf >450msec for men or women on EKG. Note: Participants may qualify for the study if QTc 450-480 msec on one EKG, but then <=450 msec on repeat EKG. If QT-prolonging medications are started or increased in dose after enrollment and prior to ketamine administration, a repeat EKG must be done >12-hours after this change in order to assure continued safe enrollment in the trial.
6. Active suicidal intent or suicidal or non-suicidal self-injurious behaviors, as defined by a "yes" response to question 4 on C-SSRS within the past 6 months at screening or prior to dosing (Active Suicidal Ideation with Some Intent to Act, with or without Specific Plan).
7. Suicidal behaviors within the last 6 month. 8. History of allergy or hypersensitivity reaction to ketamine. 9. History of ketamine use disorder. 10. History of intracranial bleeding or stroke. 11. Current intracranial mass. 12. Seizure within the last 6 months prior to screening visit. 13. Baseline oxygen saturation <95%. 14. Current significant liver disease. 15. Meets the following laboratory parameters:
-
Any significant liver diseases or symptoms of liver disease regardless of liver enzyme levels.
-
Asymptomatic alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >=5x upper limit of normal (ULN).
-
Symptomatic ALT or AST >= 2x ULN.
-
AST/ALT >3 upper limit of normal (ULN)
-
Total bilirubin > 1.5x ULN (Gilbert syndrome is allowed).
-
Alkaline phosphatase (ALP) >2x ULN.
-
Renal insufficiency (i.e., estimated glomerular filtration rate (eGFR) < 30 milliliter/minute (mL/min) /1.73 m^2 (using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation), Creatinine Clearance (CrCl) < 30 mL/min (using the Cockcroft-Gault Equation), or current dialysis)).
16. Currently pregnant or breastfeeding. 17. Has uncontrolled insulin-dependent diabetes and has had a hospitalization for diabetes-related complication within 6 months of signing ICF.
18. Diagnosed cognitive impairments, including dementia, mild cognitive impairment, traumatic brain injury, or developmental delays, that would prevent the participant from completing the study protocol, as identified by self-disclosure when asked in eligibility screening question.
19. Individuals prescribed monoamine oxidase inhibitors.(see Appendix 1) 20. Individuals prescribed medications that are CYP2B6 inhibitors or inducers (see Appendix 1) 21. Patients taking >2 mg of lorazepam-equivalents per day.
-
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Ketamine-Assisted Psychotherapy Plus Mindfulness-Oriented Recovery Enhancement (KetaMORE)
Participants assigned to this arm will receive ketamine-assisted psychotherapy combined with Mindfulness-Oriented Recovery Enhancement (MORE). MORE is delivered as a structured, manualized behavioral intervention designed to reduce opioid use by targeting craving, negative affect, and maladaptive reward processing through mindfulness training, cognitive reappraisal, and savoring techniques. |
Ketamine will be administered as part of ketamine-assisted psychotherapy under medical supervision according to the study protocol. Ketamine dosing and administration procedures will be identical across study arms. Mindfulness-Oriented Recovery Enhancement is a manualized, evidence-based intervention integrating mindfulness practices, cognitive reappraisal, and savoring exercises to reduce craving, improve emotional regulation, and support recovery from opioid use disorder. MORE sessions are delivered in a group format and coordinated with ketamine-assisted psychotherapy sessions. |
|
Aktywny komparator: Ketamine-Assisted Psychotherapy Plus Support Group
Participants assigned to this arm will receive ketamine-assisted psychotherapy combined with a support group intervention. The support group provides nonspecific therapeutic support and group discussion but does not include mindfulness training or structured skills from Mindfulness-Oriented Recovery Enhancement. |
Ketamine will be administered as part of ketamine-assisted psychotherapy under medical supervision according to the study protocol. Ketamine dosing and administration procedures will be identical across study arms. The support group intervention consists of therapist-led group sessions focused on emotional support and discussion of recovery-related experiences. This condition is designed to match the MORE intervention in duration and therapist contact while excluding mindfulness-based or structured skills training. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Abstinence
Ramy czasowe: From day 15 through 84.
|
Abstinence as measured by timeline followback and triangulated by drug screen. |
From day 15 through 84.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
MOUD discontinuation
Ramy czasowe: From day 15 to 84.
|
Discontinuation of medications for opioid use disorder (MOUD), defined as cessation of prescribed MOUD during the study period using the Timeline Follow-back and biochemically verified use via drug screens. |
From day 15 to 84.
|
|
Opioid Craving (Ecological Momentary Assessments)
Ramy czasowe: From baseline through week 12.
|
Opioid craving assessed using ecological momentary assessment (EMA) on a 0-10 numeric rating scale (0=no craving, 10 extreme craving). |
From baseline through week 12.
|
|
Opioid Craving (Desires for Drug Questionnaire)
Ramy czasowe: From baseline to week 12.
|
Opioid craving measured using the Desires for Drug Questionnaire (DDQ), a validated self-report measure of desire and urge to use opioids (0= Strongly Disagree, 6= Strongly Agree) |
From baseline to week 12.
|
|
Quality of life (WHO-5)
Ramy czasowe: From baseline to week 12.
|
Quality of life assessed using the World Health Organization Five Well-Being Index (WHO-5), a brief measure of subjective psychological well-being. (0= At no time, 5= All of the time) |
From baseline to week 12.
|
|
Depressive Symptoms (Patient Health Questionnaire-9)
Ramy czasowe: From baseline to week 12.
|
Depressive symptom severity assessed using the Patient Health Questionnaire-9 (PHQ-9). (0= Not at all, 3= Nearly every day) |
From baseline to week 12.
|
|
Post-Traumatic Stress Symptoms (PTSD Checklist for DSM-5)
Ramy czasowe: From baseline to week 12.
|
Post-traumatic stress symptom severity assessed using the PTSD Checklist for DSM-5 (PCL-5). (0 = Not at all, 4= Extremely ) |
From baseline to week 12.
|
|
Anhedonia (Snaith-Hamilton Pleasure Scale)
Ramy czasowe: From baseline to week 12.
|
Anhedonia assessed using the Snaith-Hamilton Pleasure Scale (SHAPS), a validated measure of reduced capacity to experience pleasure. (1=Strongly Disagree, 4= Strongly Agree) |
From baseline to week 12.
|
|
Psychological Distress (Depression Anxiety Stress Scales)
Ramy czasowe: From baseline to week 12.
|
Psychological distress assessed using the Depression Anxiety Stress Scales (DASS). (0= Did not apply to me at all, 3= Applied to me very much or most of the time) |
From baseline to week 12.
|
|
Positive and Negative Affect (Positive and Negative Affect Schedule)
Ramy czasowe: From baseline to week 12.
|
Positive and negative affect assessed using the Positive and Negative Affect Schedule (PANAS). (1= Very slightly or not at all, 5= Extremely) |
From baseline to week 12.
|
|
Pain (PEG Scale)
Ramy czasowe: Baseline to week 12.
|
Pain severity and pain-related interference assessed using the PEG scale. (0= no pain or interference, 10= Worst imaginable pain or interference) |
Baseline to week 12.
|
|
Momentary affective state
Ramy czasowe: Baseline through week 12.
|
Momentary affective state measured by EMA on 0-10 numeric rating scale (0=low affect, 10=high affect). |
Baseline through week 12.
|
Współpracownicy i badacze
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Zaburzenia związane z narkotykami
- Zaburzenia psychiczne
- Zaburzenia związane z substancjami
- Zaburzenia wywołane chemicznie
- Zaburzenia związane z opioidami
- Organiczne chemikalia
- Węglowodory
- Cykloheksany
- Cykloparafiny
- Węglowodory, Alicyklic
- Węglowodory, cykliczne
- Organizacje
- Ekonomia i organizacje opieki zdrowotnej
- Ketamina
- Grupy samopomocy
Inne numery identyfikacyjne badania
- 177164
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
De-Identified participant data will be shared for approved purposes with assigned data access agreement (i.e., meta-analysis)
Ramy czasowe udostępniania IPD
Data will be available after publication of the primary, secondary, and mechanistic outcomes of the trial.
Kryteria dostępu do udostępniania IPD
Data will be available with a signed data access agreement
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .